Evaluation of anti-manic activity of pregabalin in a mouse model of methylphenidate-induced mania

• Authors: Natalia MALIKOWSKA , Anna GRZYWA , Joanna ŚLADOWSKA , Kinga SAŁAT , Tadeusz LIBROWSKI , Joanna GDULA-ARGASIŃSKA
• Languages of publication: EN EO

Abstracts

EN

Mania is a psychiatric disorder which may occur alternately with depression as a bipolar disorder, or much less often as an individual disease. It might be accompanied by other disorders, i.e. schizophrenia, dementia or withdrawal syndrome. Only a few effective drugs are used for the treatment of mania. Patients suffering from bipolar disorder are treated with mood-stabilizing drugs, administered during the course of the disease, and drugs that are implemented when mania or depression episodes occur. Some studies report effectiveness of anticonvulsant drugs in the cessation of mania, thus in our study we assessed the effectiveness of pregabalin in a mouse model of mania induced by administration of metylphenidate (5 mg/kg; s.c). Pregabalin was tested in the forced swim test (75 mg/kg, 100 mg/kg; i.p.) and the elevated plus maze test (75 mg/kg; i.p.) to assess its antidepressant-like and anxiolytic-like properties, respectively. In the elevated plus maze in MPH-treated mice pregabalin significantly reduced time spent in open arms (p<0.001 vs. MPH-treated control). In the forced swim test MPH compared to vehicle significantly (p<0.001) reduced duration of immobility. In MPH-treated mice pregabalin partially reversed this effect of MPH. This effect was significant only for the dose of 75 mg/ kg (p<0.05). In the rotarod test neither MPH, nor its combination with pregabalin (75 mg/kg; 100 mg/kg) influenced motor coordination of mice at any speed tested. To conclude our study revealed that pregabalin might reverse manic-like action of MPH related to hyperlocomotion, which may indicate for its possible effectiveness in mania episodes.

Keywords

EN

anxiety; bipolar disorder; depression; mania; metylphenidate; pregabalin

Discipline

• PHARMACOLOGY: PHARMACOLOGY

• Journal: Medicina Internacia Revuo
• Year: 2017
• Volume: 28
• Issue: 108
• Pages: 196-201

Contributors

author

Natalia MALIKOWSKA

author

Anna GRZYWA

author

Joanna ŚLADOWSKA

author

Kinga SAŁAT

• Department of Pharmacodynamics, Faculty of Pharmacy, Jagiellonian University, Medyczna 9, PL 30-688 Cracow

author

Tadeusz LIBROWSKI

author

Joanna GDULA-ARGASIŃSKA

References

• 1. Muneer, A. Chonnam Med. J. 2017, 53, 1-13.
• 2. Geddes, J.R.; Briess D. BMJ Clin. Evid. 2007, 1014.
• 3. Cipriani, A.; Saunders, K.; Attenburrow, M.J.; Stefaniak, J.; Panchal, P.; Stockton, S.; Lane, T.A.; Tunbridge, E.M.; Geddes, J.R.; Harrison, P.J. Mol. Psychiatry 2016, 21, 1324–1332.
• 4. Ashok, A.H.; Marques, T.R.; Jauhar, S.; Nour, M.M.; Goodwin, G.M.; Young, A.H.; Howes, O.D. Mol. Psychiatry. 2017. Doi: 10.1038/Mp.2017.16
• 5. Gitlin, M. Int. J. Bipolar Disord. 2016, 4, 27.
• 6. De Fazio, P.; Gaetano, R,; Caroleo, M.; Pavi, M.; De Sarro, G.; Fagiolini, A.; Sequra-Garcia, C. Neuropsychiatr. Dis. Treat. 2017, 13, 755–766.
• 7. Sahraian, A.; Bigdeli, M.; Ghanizadeh, A.; Akhondzadeh, S. J. Affect. Disord. 2014, 166, 201–205.
• 8. Solmi, M.; Veronese, N.; Zaninotto, L.; Van Der Loos, M.L.M.; Gao, K.; Schaffer, A.; Reis, C.; Normann, C.; Anghelescu, I.G.; Corrnell, C.U. CNS Spectr. 2016, 21, 403–418.
• 9. Salat, K.; Gawlik, K.; Witalis, J.; Pawlica- Gosiewska, D.; Filipek, B.; Solnica, B.; Więckowski K.; Malawska B. Naunyn. Schmiedebergs. Arch. Pharmacol. 2013, 386, 493–505.
• 10. Salat, K.; Cios, A.; Wyska, E.; Salat, R.; Mogilski, S.; Filipek, B.; Wieckowski, K.; Malawska, B. Pharmacol. Biochem. Behav. 2014, 122, 173–181.
• 11. Toth, C. Ther. Adv. Drug Saf. 2014, 5, 38–56.
• 12. Salat, R.; Salat, K. J. Pharmacol. Toxicol. Methods 2015, 71, 95–102.
• 13. Argoff, C. Evid. Based Med. 2017, 22, 70–71.
• 14. Li, F.; Ma, J.; Kuang, M.; Jiang, X.; Wang, Y.; Lu, B.; Zhao, X.; Sun, L.; Ma, X. J. Orthop. Surg. Res. 2017, 12, 49.
• 15. Buoli, M.; Caldiroli, A.; Serati, M. Expert Opin. Drug Metab. Toxicol. 2017, 13, 351–359.
• 16. Barbosa, F.J.; Hesse, B.; Almeida, R.D.B.; Baretta, I.P.; Boerngen-Lacerda, R.; Andreatini, R. Pharmacol. Rep. 2011, 63, 64–70.
• 17. Tonelli, D.A.G.; Pereira, M.; Siba, I.P.; Martynhak, B.J.; Correia, D.; Casarotto, P.C.; Biojone, C.; Guimaraes, F.S.; Joca, S.L.; Andreatini R. Fundam. Clin. Pharmacol. 2013, 27, 650–655.
• 18. Souza, L.S.; Silva, E.F.; Santos, W.B.; Asth, L.; Lobão-Soares, B.; Soares-Rachetti, V.P.; Madeiros, I.U.; Gavioli, E.C. Neurosci. Lett. 2016, 629, 143– 148.
• 19. Van Den Buuse, M.; Garner, B.; Gogos, A.; Kusljic, S. J. Psychiatry 2005, 39, 550–557.
• 20. Salat, K.; Podkowa, A.; Kowalczyk, P.; Kulig, K.; Dziubina, A.; Filipek, B.; Librowski, T. Pharmacol. Rep. 2015a, 67, 465–472.
• 21. Porsolt, R.D.; Bertin, A.; Jalfre, M. Arch. Int. Pharmacodyn. Thérapie 1977, 229, 327–336.
• 22. Salat, K.; Siwek, A.; Starowicz, G.; Librowski, T.; Nowak, G.; Drabik, U.; Gajdosz, R.; Popik, P. Neuropharmacology 2015b, 99, 301–307.
• 23. Łaczkowski, K.Z.; Salat, K.; Misiura, K.; Podkowa, A.; Malikowska, N. J. Enzyme Inhib. Med. Chem. 2016, 31, 1576-1582.
• 24. Post, R.M.; Altshuler, L.L.; Leverich, G.S.; Frye, M.A.; Nolen, W.A.; Kupka, R.W.; Suppes, T.; Mcelroy, S.; Keck, P.E.; Denicoff, K.D.; Grunze, H.; Walden, J.; Kitchen, C.M.; Mintz, J. Br. J. Psychiatry 2006, 189, 124–131.
• 25. Burdick, K.E.; Braga, R.J.; Nnadi, C.U.; Shaya, Y.; Stearns, W.H.; Malhotra, A.K. J. Clin. Psychiatry 2012, 73, 103–112.
• 26. Kluge, M.; Hegerl, U.; Sander, C.; Dietzel, J.; Mergl, R.; Bitter, I.; Demyttenaere, K.; Gusomao, R.; Gonzalez-Pinto, A.; Perez-Sola, V.; Vieta,nE.; Juckel, G.; Zimmermann, U.S.; Bauer, M.; Sienaert, P.; Quintao, S.; Edel, M.A.; Bolyos, C.; Ayuso-Mateos, J.L.; Lopez-Garcia, P. BMC Psychiatry 2013, 13, 71.
• 27. Zohar, J.; Matar, M.A.; Ifergane, G.; Kaplan, Z.; Cohen, H. Eur. Neuropsychopharmacol. 2008, 18, 653–666.
• 28. Lotarski, S.M.; Donevan, S.; El-Kattan, A.; Osgood, S.; Poe, J.; Taylor, C.P.; Offord, J. J. Pharmacol. Exp. Ther. 2011, 338, 615–621.
• 29. La Porta, C.; Lara-Mayorga, I.M.; Negrete, R.; Maldonado, R. Eur. J. Pain 2016, 20, 1454–1466.
• 30. Castagné, V.; Porsolt, R.D.; Moser, P. Eur. J. Pharmacol. 2009, 616, 128–133.
• 31. Hannestad, J.O.; Cosgrove, K.P.; Della Gioia, N.F.; Perkins, E.; Bois, F.; Bhagwagar, Z.; Seibyl, J.P.; Mcclure-Begley, T.D.; Picciotto, M.R.; Esterlis, I. Biol. Psychiatry 2013, 74, 768–776.
• 32. Chiapponi, C.; Piras, F.; Piras, F.; Caltagirone, C.; Spalletta, G. Front. Psychiatry 2016,7, 61.
• 33. Brady, R.O.; Mccarthy, J.M.; Prescot, A.P.; Jensen, J.E.; Cooper, A.J.; Cohen, B.M.; Renshaw, P.F.; Ongur, D. Bipolar Disord. 2013, 15, 434–439.
• 34. Bhagwagar, Z.; Wylezinska, M.; Jezzard, P.; Evans, J.; Ashworth, F.; Sule, A.; Matthews, P.M.; Cowen, P.J. Biol. Psychiatry 2007, 61, 806–812.
• 35. Patel, R.; Dickenson, A.H. Pharmacol. Res. Perspect. 2016, 4, E00205.
• 36. Reinares, M.; Rosa, A.R.; Franco, C.; Goikolea, J.M.; Fountoulakis, K.; Siamouli, M.; Gonda, X.; Frangou, S.; Vieta, E. Int. J. Neuropsychopharmacol. 2013, 16, 485–496.
• 37. Schaffer, L.C.; Schaffer, C.B.; Miller, A.R.; Manley, J.L.; Piekut, J.A.; Nordahl, T.E. J. Affect. Disord. 2013, 147, 407–410.

• Document Type: article